Clinical Trials Directory

Trials / Conditions / Unresectable Triple-Negative Breast Carcinoma

Unresectable Triple-Negative Breast Carcinoma

11 registered clinical trials studyying Unresectable Triple-Negative Breast Carcinoma — 6 currently recruiting.

StatusTrialSponsorPhase
RecruitingTesting the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-
NCT07137416
National Cancer Institute (NCI)Phase 1
Not Yet RecruitingPropranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor R
NCT05741164
Emory UniversityPhase 2
RecruitingPersonalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B
NCT06324240
Emory UniversityPhase 1
WithdrawnTesting the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre
NCT06590558
National Cancer Institute (NCI)Phase 1
WithdrawnDendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negat
NCT05539365
Roswell Park Cancer InstitutePhase 2
TerminatedRintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastat
NCT05756166
Roswell Park Cancer InstitutePhase 1 / Phase 2
RecruitingTesting the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel)
NCT05673200
National Cancer Institute (NCI)Phase 1
RecruitingTesting the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard
NCT05422794
National Cancer Institute (NCI)Phase 1
RecruitingPersonalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli
NCT05269381
Mayo ClinicPhase 1 / Phase 2
Active Not RecruitingTesting the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
NCT04345913
National Cancer Institute (NCI)Phase 1 / Phase 2
Active Not RecruitingA Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613
National Cancer Institute (NCI)Phase 2